Hepatitis C Treatment Eligibility and Comorbid Medical Illness in Methadone Maintenance (MMT) and Non-MMT Patients: A Case-Control Study

ABSTRACT Comorbid medical illness is common in patients with chronic hepatitis C (HCV) infection and in methadone treatment (MMT) patients, yet little is known about the impact of medical illness on HCV treatment eligibility. Medical illness and HCV treatment eligibility were compared in a case-control study of 80 MMT patients entering an HCV treatment trial and 80 matched non-MMT patients entering HCV treatment in a gastroenterology clinic. 91% of MMT and 85% of non-MMT patients had chronic medical conditions. Despite similar medical severity ratings, a significantly higher proportion (77%) of non-MMT patients were eligible for HCV treatment than were MMT patients (56%) (p < .01). Specific comorbid medical and psychiatric illness led to ineligibility in only 18% of MMT and 16% of non-MMT patients. However, failure to complete the medical evaluation process was significantly (p < .001) more likely to cause ineligibility among MMT patients (19%) than non-MMT patients (0%).

[1]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[2]  D. Dieterich,et al.  Hepatitis C patients’ self‐reported adherence to treatment with pegylated interferon and ribavirin , 2008, Alimentary pharmacology & therapeutics.

[3]  G. Treisman,et al.  Medical Consequences of Drug Abuse and Co-Occurring Infections , 2008, Substance abuse.

[4]  J. Montaner,et al.  A review of barriers and facilitators of HIV treatment among injection drug users , 2008, AIDS.

[5]  D. Vlahov,et al.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Kalichman Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions. , 2008, Psychosomatic medicine.

[7]  P. Halkitis,et al.  Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. , 2008, AIDS patient care and STDs.

[8]  F. Vocci,et al.  Clinical Management of Drug Addicts Infected with Human Immunodeficiency Virus and Hepatitis C Virus , 2008, Journal of addictive diseases.

[9]  Z. Goodman Grading and staging systems for inflammation and fibrosis in chronic liver diseases. , 2007, Journal of hepatology.

[10]  D. D. Des Jarlais,et al.  HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. , 2007, The International journal on drug policy.

[11]  A. Butt,et al.  Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. , 2007, Journal of viral hepatitis.

[12]  R. Stravitz,et al.  Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3 , 2007, The American Journal of Gastroenterology.

[13]  Richard D Moore,et al.  Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic , 2006, AIDS.

[14]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[15]  E. Bini,et al.  Black patients with chronic hepatitis C have a lower sustained viral response rate than non‐Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin * , 2006, Journal of viral hepatitis.

[16]  C. B. Hare,et al.  Comparison of characteristics of treated and non‐treated patients with Hepatitis C infection , 2006, Pharmacoepidemiology and drug safety.

[17]  A. Alberti,et al.  Review article: chronic hepatitis C – natural history and cofactors , 2005, Alimentary pharmacology & therapeutics.

[18]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[19]  D. Sylvestre Approaching treatment for hepatitis C virus infection in substance users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Vocci,et al.  Medical management of HIV-hepatitis C virus coinfection in injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Fortin,et al.  Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. , 2005, Journal of clinical epidemiology.

[22]  E. McCance-Katz,et al.  Medical Illness and Comorbidities in Drug Users: Implications for Addiction Pharmacotherapy Treatment , 2005, Substance use & misuse.

[23]  W. Wadland,et al.  Medical comorbidity in addictive disorders. , 2004, The Psychiatric clinics of North America.

[24]  W. Häuser,et al.  Biopsychosocial Predictors of Health-Related Quality of Life in Patients With Chronic Hepatitis C , 2004, Psychosomatic medicine.

[25]  A. Bulbena,et al.  Medical Assessment in Drug Addicts: Reliability and Validity of the Cumulative Illness Rating Scale (Substance Abuse Version) , 2004, European Addiction Research.

[26]  P. Killenberg,et al.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.

[27]  B. Yawn,et al.  Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat , 2004, The Annals of Family Medicine.

[28]  Richard Saitz,et al.  Burden of medical illness in drug- and alcohol-dependent persons without primary care. , 2004, The American journal on addictions.

[29]  M. Busch,et al.  Hepatitis C virus seroconversion among young injection drug users: relationships and risks. , 2002, The Journal of infectious diseases.

[30]  J. Hoofnagle,et al.  National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002 , 2002, Hepatology.

[31]  J. Hoofnagle,et al.  National institutes of health consensus development conference: Management of hepatitis C: 2002 , 2002 .

[32]  D. Sylvestre Treating hepatitis C in methadone maintenance patients: an interim analysis. , 2002, Drug and alcohol dependence.

[33]  K. Delucchi,et al.  A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. , 2002, Drug and alcohol dependence.

[34]  A. McCullough,et al.  Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C , 2002, Annals of Internal Medicine.

[35]  B. Luxon,et al.  Limited success of HCV antiviral therapy in United States veterans , 2002, American Journal of Gastroenterology.

[36]  R. Fontana,et al.  Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C , 2001, American Journal of Gastroenterology.

[37]  K. Seal,et al.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? , 2001, The New England journal of medicine.

[38]  G. Davis,et al.  Treatment of chronic hepatitis C in active drug users. , 2001, The New England journal of medicine.

[39]  M. Backmund,et al.  Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.

[40]  J. Henne,et al.  The impact of homophobia, poverty, and racism on the mental health of gay and bisexual Latino men: findings from 3 US cities. , 2001, American journal of public health.

[41]  Z. Goodman,et al.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.

[42]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[43]  D. Vlahov,et al.  Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland , 1997, Journal of clinical microbiology.

[44]  D. Vlahov,et al.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. , 1996, American journal of public health.

[45]  J D Sapira,et al.  The Medical Complications of Drug Addiction and the Medical Assessment of the Intravenous Drug User: 25 Years Later , 1993, Annals of Internal Medicine.

[46]  Y. Conwell,et al.  Validation of a Measure of Physical Illness Burden at Autopsy: The Cumulative Illness Rating Scale , 1993, Journal of the American Geriatrics Society.

[47]  Sati Mazumdar,et al.  Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale , 1992, Psychiatry Research.

[48]  B. Linn,et al.  CUMULATIVE ILLNESS RATING SCALE , 1968, Journal of the American Geriatrics Society.

[49]  T. Chalmers American Association for the Study of Liver Diseases , 1959 .

[50]  R. Grant,et al.  Barriers to the treatment of hepatitis C. Patient, provider, and system factors. , 2005, Journal of general internal medicine.

[51]  D. Vlahov,et al.  Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. , 2001, American journal of public health.

[52]  R H Purcell,et al.  Clinical significance of hepatitis C virus genotypes and quasispecies. , 2000, Seminars in liver disease.

[53]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[54]  D. Vlahov,et al.  Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.